Trending...
- MyMediaGuy Search Launches to Help Local Businesses Get Found on Google Maps, Search and AI - 176
- How Are Ai Founders in Silicon Valley Building Startups in Their Sleep? - 166
- Community Colleges of Ventura County to Host State of the District Event - 160
Preliminary framework pairs NeoPathology's clinical network with Qscription's enterprise integration and U.S. operations capability.
MILWAUKEE - Californer -- Qscription Technologies Inc., a U.S. market-entry and clinical AI integration company, and NEOPATHOLOGY CORP., a biotechnology research and clinical diagnostic development company, today announced a Memorandum of Understanding (MOU).
Under the preliminary framework, the companies intend to explore joint commercialization and enterprise integration of an FDA 510(k)-cleared lung imaging AI diagnostic application in select U.S. healthcare markets. NEOPATHOLOGY brings its clinical network, diagnostic expertise, and clinical onboarding capability. Qscription contributes enterprise integration and U.S. operations support.
Regulator-cleared AI applications frequently stall between clearance and everyday clinical use, held up by IT integration, security review, and onboarding complexity. Under the proposed framework, NEOPATHOLOGY would lead clinical strategy, including securing programs, clinical onboarding, and region-specific medical compliance. Qscription would lead enterprise integration through its MedTech Operations capability, including integration with provider PACS and EHR environments, in material compliance with applicable HIPAA Security Rule and FDA requirements.
More on The Californer
"Clinical AI does not fail on science. It fails on integration and adoption," said Anurag Velekkatt Sunil Kumar, VP, MedTech Partnerships at Qscription Technologies. "NeoPathology's clinical network and commercialization strength, combined with our enterprise integration and U.S. operations capability, make a complete offering for the providers we serve."
"Our mission at NEOPATHOLOGY has always been centered on delivering highly accurate, rapidly reported diagnostics that meaningfully improve patient outcomes," said Paul Aiyetan, M.D., M.S., Ph.D., CEO and Director of Research, Development and Translation at NEOPATHOLOGY CORP. "Securing regulatory clearance is a critical milestone, but it is not the finish line. This MOU represents our proactive approach to ensuring that breakthrough tools can be safely, compliantly, and efficiently integrated into the hands of providers. By pairing our clinical development depth with Qscription's technical deployment framework, we are charting a reliable course from validation to clinical adoption."
The companies are now working toward a definitive commercial deployment agreement.
About NEOPATHOLOGY CORP.
NEOPATHOLOGY CORP. is a biotechnology research and clinical diagnostic development company advancing highly accurate, rapidly reported precision tissue diagnostics, anchored by its proprietary diagnostics platform and ONEPATHOLOGY(TM) learning solution. NEOPATHOLOGY is a Delaware corporation headquartered in Frederick, Maryland. https://neopathology.bio
More on The Californer
About Qscription Technologies
Qscription Technologies is the U.S. market-entry partner for global MedTech and clinical AI companies. Through its Decipher(TM) framework, Qscription provides regulatory presence, market access, enterprise integration, and U.S. operations support, turning FDA-cleared products into adopted products. Qscription is a Delaware corporation headquartered in Jackson, Wisconsin. https://qscription.tech
Read more: https://qscription.tech/blog/qscription-neopathology-mou
Media contacts
Qscription: Ajeesh Kumar, CTO, +1 715 449 8977
NEOPATHOLOGY: Paul Aiyetan, M.D., M.S., Ph.D., +1 (202) 810 3614
Under the preliminary framework, the companies intend to explore joint commercialization and enterprise integration of an FDA 510(k)-cleared lung imaging AI diagnostic application in select U.S. healthcare markets. NEOPATHOLOGY brings its clinical network, diagnostic expertise, and clinical onboarding capability. Qscription contributes enterprise integration and U.S. operations support.
Regulator-cleared AI applications frequently stall between clearance and everyday clinical use, held up by IT integration, security review, and onboarding complexity. Under the proposed framework, NEOPATHOLOGY would lead clinical strategy, including securing programs, clinical onboarding, and region-specific medical compliance. Qscription would lead enterprise integration through its MedTech Operations capability, including integration with provider PACS and EHR environments, in material compliance with applicable HIPAA Security Rule and FDA requirements.
More on The Californer
- Governor Newsom announces new swiftwater rescue fleet to strengthen California storm preparedness
- Geospatial Innovation Comes to Sacramento: FOSS4G NA 2026
- Agromin and City of Santa Clarita Announce Free Compost Giveaway Program
- Tulsa Air & Space Museum Launches "Give $16 for the F-16" Challenge to Bring Thunderbird Home for Veterans Day
- Hannk And Zubie Join Forces To Shape The Next Generation Of Connected Vehicle Telematics
"Clinical AI does not fail on science. It fails on integration and adoption," said Anurag Velekkatt Sunil Kumar, VP, MedTech Partnerships at Qscription Technologies. "NeoPathology's clinical network and commercialization strength, combined with our enterprise integration and U.S. operations capability, make a complete offering for the providers we serve."
"Our mission at NEOPATHOLOGY has always been centered on delivering highly accurate, rapidly reported diagnostics that meaningfully improve patient outcomes," said Paul Aiyetan, M.D., M.S., Ph.D., CEO and Director of Research, Development and Translation at NEOPATHOLOGY CORP. "Securing regulatory clearance is a critical milestone, but it is not the finish line. This MOU represents our proactive approach to ensuring that breakthrough tools can be safely, compliantly, and efficiently integrated into the hands of providers. By pairing our clinical development depth with Qscription's technical deployment framework, we are charting a reliable course from validation to clinical adoption."
The companies are now working toward a definitive commercial deployment agreement.
About NEOPATHOLOGY CORP.
NEOPATHOLOGY CORP. is a biotechnology research and clinical diagnostic development company advancing highly accurate, rapidly reported precision tissue diagnostics, anchored by its proprietary diagnostics platform and ONEPATHOLOGY(TM) learning solution. NEOPATHOLOGY is a Delaware corporation headquartered in Frederick, Maryland. https://neopathology.bio
More on The Californer
- Zhengxin Chicken Steak Opens at South Hills Plaza in West Covina
- Coinfiliate Launches Platform to Helps Shoppers Earn Cashback and Creators Earn Referral Rewards
- Russ Lorenson Announces "What I Want For Christmas (20th Anniversary Edition)"
- Best Bracelet Gifts for Her in 2026: Affordable Luxury Jewellery That Looks Expensive
- Holiday Gambling Spending Expected to Rise 12% in December
About Qscription Technologies
Qscription Technologies is the U.S. market-entry partner for global MedTech and clinical AI companies. Through its Decipher(TM) framework, Qscription provides regulatory presence, market access, enterprise integration, and U.S. operations support, turning FDA-cleared products into adopted products. Qscription is a Delaware corporation headquartered in Jackson, Wisconsin. https://qscription.tech
Read more: https://qscription.tech/blog/qscription-neopathology-mou
Media contacts
Qscription: Ajeesh Kumar, CTO, +1 715 449 8977
NEOPATHOLOGY: Paul Aiyetan, M.D., M.S., Ph.D., +1 (202) 810 3614
Source: Qscription Technologies Inc
0 Comments
Latest on The Californer
- Reloworks™ Launches Perfect Saturday Morning™ Lifestyle Program Across the Bay Area
- California: Governor Gavin Newsom statement on Donald Trump's disgusting and disqualifying comments
- Learn window tinting in Los Angeles on October 24th & 25th with the Tint Academy
- Essential Clinical Resource Equips Addiction Professionals with EFT Tapping Tools That Outperform
- Postmortem Pathology Highlights Private Autopsy Options for Las Vegas Families During Summer Months
- Postmortem Pathology Offers Sacramento Families Independent Answers on a Short Timeline
- Teens Wanna Know Launches TWK Play, a Free Web Hub for Watching and Listening
- City Shares Information on Upcoming Street Closures for Long Beach Marathon
- Long Beach College & Career Expo Returns Oct. 13
- Feeling Drained? Botanical Alchemy Aura Cleanser Brings Energy Cleansing to Murrieta
- Where to stay near SoFi Stadium for a concert: Courtyard LAX/Hawthorne and the closest hotels
- City of Long Beach Announces Retirement of Director of Disaster Preparedness and Emergency Communications
- California reminds voters to check their mailboxes and return their ballot ASAP!
- NEW Three Fully Furnished Single-Family Model Homes at Heritage at South Brunswick
- Pervaziv AI Advances Cortex Discover with Resource Efficient Agentic AI, Backed by Six Browser Study
- Pervaziv AI Launches Cortex CLI, Bringing Enterprise Agentic AI to the Terminal
- After 35 Years, Christian Radio Host Marina Maria Publishes the Novel She Never Forgot
- Maximus Payments Launches Multi-Processor Merchant Services for Businesses of Every Risk Profile
- Freight Broker 911 CEO and President Milton Collier Is Rebuilding the Path Into Freight Brokerage
- Backyards Are America's New Living Rooms. Can They Survive Record U.S. Heat?